Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Midostaurin maintenance may reduce relapse risk in FLT3-ITD+ AML

Key clinical point: Midostaurin maintenance therapy after allogeneic stem cell transplant may improve relapse free survival in acute myeloid leukemia with FLT3 expression.

Major finding: Midostaurin maintenance improved relapse-free survival (hazard ratio, 0.46).

Study details: The phase 2 RADIUS trial of 60 patients with acute myeloid leukemia.

Disclosures: Dr. Maziarz reported financial relationships with Incyte, Novartis, Celgene/Juno, Kite/Gilead, Juno Therapeutics, Kite Therapeutics, and Athersys.


Transplantation and Cellular Therapy Meetings 2019